Real world low-tech solutions for a high stakes issue

BACKGROUND

It is well established that achieving optimal ratios of packed red blood cells (PRBC) to fresh frozen plasma (FFP) to platelet ratios during massive transfusion leads to improved outcomes but is difficult to accomplish.

METHODS

Between September 2018 and May 2019 our level 2 trauma center implemented 3 new processes to optimize transfusion ratios during massive transfusion protocol (MTP). Two units of low titer group O whole blood (LTOWB) were added as the first step to our MTP. Second, a dry erase board whiteboard was attached to each fluid warmer for real time recording of transfusions. Last, liquid plasma was incorporated into our MTP. We performed a retrospective review evaluating PRBC:FFP ratios for patients who had the massive transfusion protocol initiated and received 4 or more units of blood.

RESULTS

A total of 50 patients had the massive transfusion protocol initiated and received 4 or more units of PRBCs and/or LTOWB within 4 h of arrival. There were 21 patients evaluated prior to protocol changes and 29 patients after the changes. In the study group mean age, sex, pulse, systolic blood pressure (SBP), and injury severity scale (ISS) on admission were not different. In the pre-protocol (preP) group 90% of patients were blunt trauma and in the post-protocol group (postP) 72% were blunt trauma, p = 0. 22. For the preP group the mean units of PRBCs was 7.6 units and FFP 4.7 units. PostP the mean units of PRBCs was 11.4 units and FFP 10.0 units. PRBC/FFP ratios were 1.7 preP and 1.2 postP, p = 0.0072.

CONCLUSION

The institution of whole blood, use of the trauma white board, and the addition of liquid plasma to our transfusion services have allowed us to approach a 1:1 transfusion ratio during the course of our massive transfusions.

A Comparison of Growth Factors and Cytokines in Fresh Frozen Plasma and Never Frozen Plasma

BACKGROUND

Fresh frozen plasma (FFP) contains proinflammatory mediators released from cellular debris during frozen storage. In addition, recent studies have shown that transfusion of never-frozen plasma (NFP), instead of FFP, may be superior in trauma patients. We hypothesized that FFP would have higher levels of inflammatory mediators when compared to NFP.

MATERIALS AND METHODS

FFP (n = 8) and NFP (n = 8) samples were obtained from an urban, level 1 trauma center blood bank. The cytokines in these samples were compared using a Milliplex (Milliplex Sigma) human cytokine magnetic bead panel multiplex assay for 41 different biomarkers.

RESULTS

Growth factors that were higher in NFP included platelet-derived growth factor-AA (PDGF-AA; 8.09 versus 108.00 pg/mL, P < 0.001) and PDGF-AB (0.00 versus 215.20, P= 0.004). Soluble CD40-ligand (sCD40L), a platelet activator and pro-coagulant, was higher in NFP (31.81 versus 80.45 pg/mL, P< 0.001). RANTES, a leukocyte chemotactic cytokine was higher in NFP (26.19 versus 1418.00 pg/mL, P< 0.001). Interleukin-4 (5.70 versus 0.00 pg/mL, P= 0.03) and IL-8 (2.20 versus 0.52 pg/ml, P= 0.03) levels were higher in were higher in FFP.

CONCLUSIONS

Frozen storage of plasma may result in decrease of several growth factors and/or pro-coagulants found in NFP. In addition, the freezing and thawing process may induce release of pro-inflammatory chemokines. Further studies are needed to determine if these cytokines result in improved outcomes with NFP over FFP in transfusion of trauma patients.

Acoustic cavitation assisted plasma for wastewater treatment: Degradation of Rhodamine B in aqueous solution

A novel wastewater treatment process, acoustic cavitation assisted plasma (ACAP) is proposed in this study aiming at expanding the treatable range of water pollutants due to a synergetic effect of ultrasound irradiation and high voltage plasma discharge. In this process, the role of acoustic cavitation is not only to provide generation of chemically active OH radicals, as for example in conventional ultrasonic wastewater treatment techniques, but also to ensure conditions for stable plasma generation in wastewater and, thus, to extend the treatable range of water pollutants. Rhodamine B (RhB) was used as a model pollutant in experiments examining effects of ultrasound amplitude, RhB initial concentration, output voltage, solution pH and electrical conductivity on the RhB degradation efficiency. The results revealed that the ultrasound-assisted plasma generation requires lower output voltages and allows to increase the acceptable range of electrical conductivity of treatable solutions up to 1000 μS/cm, that is about 24 times higher than in the case of conventional plasma discharge treatment. The alkaline and acid medium were found to be favorable for higher degradation efficiency. Additional measurements and results of recent investigations concerning underwater plasma showed that microbubbles presented in cavitation zone could serve as "bridges" making the pulse discharge propagation between the electrodes easier than in the conventional case. Besides, acoustic cavitation assists a faster transition of plasma discharge from ineffective streamer type to more effective spark type that further contributes to the improvement of the treatment performance.

Plasma for direct therapeutic use, for today and tomorrow: A short critical overview

Plasma for direct therapeutic use is a fast-evolving blood component in terms of its production and presentation. More than a dozen forms are available worldwide, which is often overlooked since most countries apply policies making only one or very few forms available for treating patients in need. It is most often reserved for the same three clinical indications, i.e. overall clotting-factor deficiency, reversal of vitamin K antagonists in the context of active bleeding or prior to urgent surgery, and therapeutic plasma exchange. The level of evidence is often less robust than generally acknowledged for such major indications while novel indications are tending to emerge in medical and trauma settings. This short review explores classical views and new prospects opened up by novel presentations and statuses for therapeutic plasma.